# Durvalumab Long-Term Safety and Efficacy Study

> **NCT04078152** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 163 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04078152
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-05
- **Primary completion:** 2022-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04078152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04078152, "Durvalumab Long-Term Safety and Efficacy Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04078152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*